Showing 2821-2830 of 5685 results for "".
- Myco Industries Debuts AB Max Advanced for Treatment of Anterior Blepharitishttps://modernod.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/Myco Industries released AB MAX, a new treatment for anterior blepharitis. The AB MAX is an adapter that allows eye care professionals to increase the functionality of their Algerbrush by converting it into a multi-purpose device for treatment of the same conditions as a standard Algerbrush, as w
- FDA Grants Breakthrough Device Designation to Concussion Assessment Devicehttps://modernod.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/SyncThink announced that the FDA has granted Breakthrough Device Designation to EYE-SYNC, an objective eye-tracking platform. The EYE-SYNC platform is used to assist clinicians in evaluating visual impairments, monitor recovery, and support the rehabilitation of ocular-motor and ocular-vestibular
- Novartis Issues Summary Financial Information for the Alcon Eye Care Business Ahead of Shareholder Votehttps://modernod.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019. The issuance of the short form fi
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- WSJ: Roche Nears Deal to Buy Spark Therapeutics for Close to $5 Billionhttps://modernod.com/news/wsj-roche-nears-deal-to-buy-spark-therapeutics-for-close-to-5-billion/2476269/Swiss pharmaceutical company Roche is nearing a deal to buy Philadelphia-based biotechnology company Spark Therapeutics, according to a report in the Wall Street Journal
- AbbVie’s Humira (Adalimumab) Approved by Health Canada to Treat Pediatric Patients with Chronic Noninfectious Anterior Uveitishttps://modernod.com/news/abbvies-humira-adalimumab-approved-by-health-canada-to-treat-pediatric-patients-with-chronic-noninfectious-anterior-uveitis/2476279/AbbVie announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic noninfectious anterior uveitis in pediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropr
- Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for Xiperehttps://modernod.com/news/clearside-biomedical-receives-notification-of-fda-acceptance-of-nda-filing-for-xipere/2476281/Clearside Biomedical announced that the FDA has accepted for review the company’s new drug application (NDA) for Xipere (triamcinolone acetonide ophthalmic suspension) for suprachoroidal injection for the treatment of macular edema associated with uveitis. The FDA has determined that the ap
- Alcon Debuts iLux MGD Treatment System at SECOhttps://modernod.com/news/alcon-debuts-ilux-mgd-treatment-system-for-personalized-therapy-for-dry-eye-disease-at-seco/2476284/Alcon debuted the iLux MGD Treatment System at the SECO International 2019 annual meeting in New Orleans. The device, which received approval from the FDA in December 2017, helps eye care professionals provide comprehensive, in-office
- Registration Now Open for Neuro-Optometric Rehabilitation Association Meetinghttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-meeting/2476291/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 19-20) and 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona. The
- Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-ocu400-gene-therapy-for-retinal-degenerative-disease/2476293/Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual i